We are monitoring the impact of COVID-19 on MEA Monoclonal Antibodies Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1139
Share on
Share on

Middle East & Africa Monoclonal Antibodies Market Research Report – Segmented By Source, Indication, End-User, Application, Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis, Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1139
Pages: 129

MEA Monoclonal Antibodies Market Size (2021 To 2026)

The size of the Middle East and Africa monoclonal antibodies market was worth USD 3.39 Billion in 2021 and estimated to be growing at a CAGR of 12.95%, to reach USD 6.23 Billion by 2026.

Monoclonal is a class of antibodies with the identical progeny of a hybridoma, derived by cell division from a single ancestral cell.

MARKET DRIVERS:

The growing demand for personalized medicine is a vital factor responsible for developing therapeutic antibodies to provide targeted therapies, as each individual responds differently to a particular treatment. Furthermore, the advantages associated with using monoclonal antibodies for therapeutic purposes, including reducing adverse effects, homogeneity, specificity, and large-scale production, contribute to significant market growth. Moreover, increasing research collaborations to develop a strong drug portfolio is an important factor that is expected to drive the MEA monoclonal antibodies market growth during the forecast period.

In addition, government initiatives aimed at enabling the cost-effective production of monoclonal antibodies are expected to foster the emergence of this sector during the forecast period. For example, the National Institute of Standards and Technology's Biologic Manufacturing Initiative provides scientifically sound regulatory guidance to ensure the efficient and safe manufacture of protein therapies and help biopharmaceutical manufacturers deliver high-quality protein drugs for a low-cost region-wide. In addition, technological advancements in immunoassay offer a growth opportunity in the market.

The growing number of coronavirus cases increases the need for precise treatment options, leading to the development of monoclonal antibodies and, therefore, would help the monoclonal antibody market grow significantly in the years to come. Unlimited production and identification of specific clones against a particular antigen make this a unique product designed with ease in laboratories.

The growth of the MEA monoclonal antibodies market would be challenged by the high cost involved in developing therapeutic monoclonal antibodies, the threats associated with counterfeit drugs, and the legal regulations required for the identification of molecules are important factors limiting the growth of the market.

MARKET RESTRAINTS:

A disadvantage of drugs formulated from monoclonal antibodies is that they are particular in nature and have limited purposes. This is because they interact with cells and do not penetrate them. To some extent, this has hampered the global monoclonal antibody market. Another difficulty in using monoclonal antibodies is that they have to be injected, unlike small molecule drugs.

The production and maintenance of infrastructure are expensive and often difficult, especially in low-income, underdeveloped countries.

This research report on the MEA monoclonal antibodies market has been segmented & sub-segmented into the following categories:

By Source: 

  • Murine
  • Chimeric
  • Humanized
  • Human

By Indication: 

  • Cancer
    • Blood Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Pancreatic Cancer
    • Others
  • Autoimmune Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • CNS Disorders
  • Others (Inflammatory, Microbial Diseases, & Other)

By End-User: 

  • Hospitals/Clinics
  • Research Institute
  • Diagnostic Laboratories

By Application: 

  • Medical
  • Experimental
  • Western Blot
    • ELISA
    • Radioimmune Assays
    • Immunofluorescence
    • Others

By Country:

  • KSA
  • UAE
  • Israel
  • Rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • Rest of MEA

Regional Analysis

Saudi Arabia is the most dominant regional market in the monoclonal antibody therapeutics market in the Middle East and Africa. It can be attributed to the presence of a well-established healthcare infrastructure. In addition, its large patient population base, well-established reimbursement policies, high disease awareness, government support for infection control and management, increasing incidence of lifestyle-associated diseases, and increased investment in R&D activities by the government for cancer contributes to the growth of Middle East participation.

The United Arab Emirates monoclonal antibodies market is predicted to showcase a lucrative growth rate. The market is growing due to the significant growth in the life sciences industry and the availability of funds from the government and non-government sectors for clinical diagnostics.

KEY MARKET PLAYERS:

GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, Seattle Genetics, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., and Biogen Inc. are expected to account for the majority of the MEA Monoclonal Antibodies Market share during the forecast period.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods  

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 By Source                    

                                5.1.1 Murine     

                                5.1.2 Chimeric   

                                5.1.3 Humanized             

                                5.1.4 Human      

                5.2 By Indication                              

                                5.2.1 Cancer      

                                                5.2.1.1 Blood Cancer

                                                5.2.1.2 Breast Cancer

                                                5.2.1.3 Colorectal Cancer

                                                5.2.1.4 Lung Cancer

                                                5.2.1.5 Pancreatic Cancer

                                                5.2.1.6 Others

                                5.2.2 Autoimmune Diseases       

                                5.2.3 Infectious Diseases             

                                5.2.4 Cardiovascular Diseases    

                                5.2.5 CNS Disorders        

                                5.2.6 Others (Inflammatory, Microbial Diseases, & Other)            

                5.3 End User                      

                                5.3.1 Hospitals/Clinics    

                                5.3.2 Research Institute

                                5.3.3 Diagnostic Laboratories     

                5.4 Application                 

                                5.4.1 Medical    

                                5.4.2 Experimental         

                                                5.4.2.1 Western Blot

                                                5.4.2.2 ELISA

                                                5.4.2.3 Radioimmune Assays 

                                                5.4.2.4 Immunofluorescence 

                                                5.4.2.5 Other (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)

6. Geographical Analysis                                              

                6.1 Middle East & Africa               

                                6.1.1 Introduction           

                                6.1.2 Middle-East            

                                6.1.3 Africa         

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                    

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                               

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target     

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

                7.5 Key Trends in Monoclonal Antibodies Development                

                                7.5.1 Targeted Therapies             

                7.6 Promising Monoclonal Antibodies in Pipeline                              

                7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Monoclonal Antibodies                 

8. Strategic Analysis                                       

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental       

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services              

                                8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                        

                9.1 GlaxoSmithKline plc (U.K.)                   

                                9.1.1 Overview 

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Novartis AG (Switzerland)                    

                9.3 Pfizer Inc. (U.S.)                       

                9.4 Thermo Fisher Scientific Inc. (U.S.)                   

                9.5 Eli Lilly and Company (U.S.)                  

                9.6 Seattle Genetics (U.S.)                          

                9.7 Bristol-Myers Squibb (U.S.)                 

                9.8 F. Hoffmann-La Roche Ltd. (Switzerland)                      

                9.9 Teva Pharmaceutical Industries Ltd. (Israel)                 

10. Competitive Landscape                                         

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                      

                10.4 New Product Launches                       

11. Market Outlook & Investment Opportunities                                             

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Middle East & Africa Monoclonal Antibodies Market By Murine, From 2021 to 2026 (USD Billion)
  2. Middle East & Africa Chimeric Market By Region, From 2021 to 2026 (USD Billion)
  3. Middle East & Africa Humanized Market By Region, From 2021 to 2026 (USD Billion)
  4. Middle East & Africa Human Market By Region, From 2021 to 2026 (USD Billion)
  5. Middle East & Africa Monoclonal Antibodies Market By Cancer, From 2021 to 2026 (USD Billion)
  6. Middle East & Africa Autoimmune Diseases Market By Region, From 2021 to 2026 (USD Billion)
  7. Middle East & Africa Infectious Diseases Market By Region, From 2021 to 2026 (USD Billion)
  8. Middle East & Africa Cardiovascular Diseases Market By Region, From 2021 to 2026 (USD Billion)
  9. Middle East & Africa CNS Disorders Market By Region, From 2021 to 2026 (USD Billion)
  10. Middle East & Africa Others (Inflammatory, Microbial Diseases, & Other) Market By Region, From 2021 to 2026 (USD Billion)
  11. Middle East & Africa Monoclonal Antibodies Market By Hospitals/Clinics, From 2021 to 2026 (USD Billion)
  12. Middle East & Africa Research Institute Market By Region, From 2021 to 2026 (USD Billion)
  13. Middle East & Africa Diagnostic Laboratories Market By Region, From 2021 to 2026 (USD Billion)
  14. Middle East & Africa Monoclonal Antibodies Market By Medical, From 2021 to 2026 (USD Billion)
  15. Middle East & Africa Experimental Market By Region, From 2021 to 2026 (USD Billion)
  16. Middle East Monoclonal Antibodies Market By Murine, From 2021 to 2026 (USD Billion)
  17. Middle East Monoclonal Antibodies Market By Cancer, From 2021 to 2026 (USD Billion)
  18. Middle East Monoclonal Antibodies Market By Hospitals/Clinics, From 2021 to 2026 (USD Billion)
  19. Middle East Monoclonal Antibodies Market By Medical, From 2021 to 2026 (USD Billion)
  20. Africa Monoclonal Antibodies Market By Murine, From 2021 to 2026 (USD Billion)
  21. Africa Monoclonal Antibodies Market By Cancer, From 2021 to 2026 (USD Billion)
  22. Africa Monoclonal Antibodies Market By Hospitals/Clinics, From 2021 to 2026 (USD Billion)
  23. Africa Monoclonal Antibodies Market By Medical, From 2021 to 2026 (USD Billion)
  24. Middle East & Africa Monoclonal Antibodies Market By Blood Cancer, From 2021 to 2026 (USD Billion)
  25. Middle East & Africa Breast Cancer Market By Region, From 2021 to 2026 (USD Billion)
  26. Middle East & Africa Colorectal Cancer Market By Region, From 2021 to 2026 (USD Billion)
  27. Middle East & Africa Lung Cancer Market By Region, From 2021 to 2026 (USD Billion)
  28. Middle East & Africa Pancreatic Cancer Market By Region, From 2021 to 2026 (USD Billion)
  29. Middle East & Africa Others Market By Region, From 2021 to 2026 (USD Billion)
  30. Middle East Monoclonal Antibodies Market By Blood Cancer, From 2021 to 2026 (USD Billion)
  31. Africa Monoclonal Antibodies Market By Blood Cancer, From 2021 to 2026 (USD Billion)
  32. Middle East & Africa Monoclonal Antibodies Market By Western Blot, From 2021 to 2026 (USD Billion)
  33. Middle East & Africa ELISA Market By Region, From 2021 to 2026 (USD Billion)
  34. Middle East & Africa Radioimmune Assays Market By Region, From 2021 to 2026 (USD Billion)
  35. Middle East & Africa Immunofluorescence Market By Region, From 2021 to 2026 (USD Billion)
  36. Middle East & Africa Others Market By Region, From 2021 to 2026 (USD Billion)
  37. Middle East Monoclonal Antibodies Market By Western Blot, From 2021 to 2026 (USD Billion)
  38. Africa Monoclonal Antibodies Market By Western Blot, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample